The Symbiotec Pharmalab IPO plans to channel Rs 112.50 crore towards the prepayment and/or repayment, fully or partially, of select outstanding borrowings, helping strengthen the company’s balance sheet and potentially reduce its debt burden.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.